Lastly, our analysis of BRPF1 expression in pan-cancer and PCa databases demonstrated its significant association with various clinical attributes, including the upregulation observed in taxane-exposed PCa patients, suggesting BRPF1 as a potential biomarker for the progression of PCa. Here, BRPF1 is linked to posterior cortical atrophy.